{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:00:12Z","timestamp":1787068812521,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.suc.2019.09.003","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:13:03Z","timestamp":1572253983000},"page":"109-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Locoregionally Advanced Melanoma"],"prefix":"10.1016","volume":"100","author":[{"suffix":"Jr.","given":"David T.","family":"Pointer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suc.2019.09.003_bib1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib2","first-page":"244","article-title":"Locoregional cutaneous metastases of malignant melanoma and their management","volume":"30","author":"Wolf","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.suc.2019.09.003_bib3","series-title":"AJCC cancer staging manual","year":"2017"},{"key":"10.1016\/j.suc.2019.09.003_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11912-013-0333-5","article-title":"Current treatment of locoregional recurrence of melanoma","volume":"15","author":"Squires","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.suc.2019.09.003_bib5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E","article-title":"Analysis of prognosis and disease progression after local recurrence of melanoma","volume":"88","author":"Dong","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CCO.0000000000000158","article-title":"Intralesional therapy for advanced melanoma: promise and limitation","volume":"27","author":"Agarwala","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14737140.2018.1444482","article-title":"Intralesional therapy as a treatment for locoregionally metastatic melanoma","volume":"18","author":"Miura","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.suc.2019.09.003_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","article-title":"The classic: the treatment of malignant tumors by repeated inoculations of erysipelas","volume":"262","author":"Coley","year":"1991","journal-title":"Clin Orthop Relat Res"},{"issue":"suppl","key":"10.1016\/j.suc.2019.09.003_bib9","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO;2-H","article-title":"Immunotherapy of guinea pig cancer with BCG","volume":"34","author":"Zbar","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib10","first-page":"831","article-title":"Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guerin","volume":"46","author":"Zbar","year":"1971","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.suc.2019.09.003_bib11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archsurg.1976.01360240096018","article-title":"BCG immunotherapy in patients with malignant melanoma","volume":"111","author":"Karakousis","year":"1976","journal-title":"Arch Surg"},{"key":"10.1016\/j.suc.2019.09.003_bib12","first-page":"95","article-title":"BCG immunotherapy in previously treated malignant melanoma patients","volume":"30","author":"Mujagic","year":"1979","journal-title":"Biomedicine"},{"key":"10.1016\/j.suc.2019.09.003_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2019.09.003_bib14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/1097-0142(197602)37:2<684::AID-CNCR2820370212>3.0.CO;2-Y","article-title":"Intralesional BCG in the treatment of metastatic malignant melanoma","volume":"37","author":"Mastrangelo","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib15","first-page":"17","article-title":"Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion","volume":"149","author":"Storm","year":"1979","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.suc.2019.09.003_bib16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/1097-0142(197510)36:4<1305::AID-CNCR2820360417>3.0.CO;2-#","article-title":"Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases","volume":"36","author":"Mastrangelo","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib17","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.20166","article-title":"Mature results of a phase III randomized trial of bacillus Calmette\u2013Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I\u2013III melanoma (E1673)","volume":"100","author":"Agarwala","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in\u00a0vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.suc.2019.09.003_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.suc.2019.09.003_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.cco.0000142070.45097.68","article-title":"A\u00a0review of recent findings involving interleukin-2-based cancer therapy","volume":"16","author":"Eklund","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jso.23556","article-title":"Intra-lesional interleukin-2 therapy for in transit melanoma","volume":"109","author":"Temple-Oberle","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib22","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib23","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High response rate after intratumoral treatment with interleukin-2","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review","volume":"110","author":"Byers","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood-2008-12-164004","article-title":"The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease","volume":"114","author":"Hercus","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.suc.2019.09.003_bib26","article-title":"Current status of granulocyte\u2013macrophage colony-stimulating factor in the immunotherapy of melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib27","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.suc.2019.09.003_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008390-199606000-00008","article-title":"Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF","volume":"6","author":"Si","year":"1996","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2019.09.003_bib29","first-page":"139","article-title":"Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells","volume":"5","author":"Nasi","year":"1999","journal-title":"Cytokines Cell Mol Ther"},{"key":"10.1016\/j.suc.2019.09.003_bib30","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1073\/pnas.90.10.4645","article-title":"Immunotherapy of malignancy by in\u00a0vivo gene transfer into tumors","volume":"90","author":"Plautz","year":"1993","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.suc.2019.09.003_bib31","doi-asserted-by":"crossref","first-page":"11307","DOI":"10.1073\/pnas.90.23.11307","article-title":"Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans","volume":"90","author":"Nabel","year":"1993","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.suc.2019.09.003_bib32","doi-asserted-by":"crossref","first-page":"15388","DOI":"10.1073\/pnas.93.26.15388","article-title":"Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes","volume":"93","author":"Nabel","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.suc.2019.09.003_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1200\/JCO.1997.15.1.341","article-title":"Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma","volume":"15","author":"Stopeck","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.cmr.0000232299.44902.41","article-title":"Phase 2 trial of Allovectin-7 in advanced metastatic melanoma","volume":"16","author":"Gonzalez","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2019.09.003_bib35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CMR.0b013e3283390711","article-title":"A\u00a0phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma","volume":"20","author":"Bedikian","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2019.09.003_bib36","unstructured":"Richards J, Thompson J, Atkins M. A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma. Proc Am Soc Clin Oncol [abstract]. Orlando, FL, May 18\u201321, 2002."},{"key":"10.1016\/j.suc.2019.09.003_bib37","unstructured":"Andtbacka RHI, Gonzalez R, Wloch MK. A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2\u00a0mg Intralesional Allovectin-7\u00ae Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma. International Meeting of the Society for Melanoma Research [abstract]. Philadelphia, November 17\u201320, 2013."},{"key":"10.1016\/j.suc.2019.09.003_bib38","first-page":"1","article-title":"T\u00a0cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1\/PD-L1 pathway in a murine melanoma model","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.suc.2019.09.003_bib39","doi-asserted-by":"crossref","first-page":"pS8","DOI":"10.1097\/00008390-200609001-00012","article-title":"Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. [abstract]","volume":"16","author":"Mousavi","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2019.09.003_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","article-title":"Chemoablation of metastatic melanoma using intralesional Rose Bengal","volume":"18","author":"Thompson","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2019.09.003_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0068561","article-title":"Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer","volume":"8","author":"Toomey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.suc.2019.09.003_bib42","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 study of intralesional PV-10 in refractory metastatic melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suc.2019.09.003_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.suc.2019.09.003_bib45","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1128\/jvi.71.8.6049-6054.1997","article-title":"Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene","volume":"71","author":"He","year":"1997","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.suc.2019.09.003_bib46","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A\u00a0phase I Study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suc.2019.09.003_bib47","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib48","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib49","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib50","unstructured":"Andtbacka R, Dummer R, Gyorki D, et\u00a0al. Interim analysis of a randomized, Open-Label phase II study of talimogene laherparepvec neoadjuvant treatment plus\u00a0surgery versus surgery for resectable stage IIIB-IVM1a melanoma. Society of Surgical Oncology 2019 Annual Meeting [abstract]. San Diego, CA, March 27\u201330, 2019."},{"key":"10.1016\/j.suc.2019.09.003_bib51","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1200\/jco.2015.33.15_suppl.9030","article-title":"Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.suc.2019.09.003_bib52","doi-asserted-by":"crossref","first-page":"P343","DOI":"10.1186\/2051-1426-3-S2-P343","article-title":"Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment","volume":"3","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.suc.2019.09.003_bib53","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1200\/JCO.2018.36.15_suppl.3092","article-title":"Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity","volume":"36","author":"Anthoney","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.suc.2019.09.003_bib54","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/mt.2012.146","article-title":"Phase II trial of intravenous administration of reolysin\u00ae (reovirus serotype-3-dearing strain) in patients with metastatic melanoma","volume":"20","author":"Galanis","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.suc.2019.09.003_bib55","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","article-title":"A\u00a0phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer","volume":"14","author":"Vidal","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suc.2019.09.003_bib56","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1200\/jco.2014.32.15_suppl.6082","article-title":"Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+\/HSV- patients with refractory and superficial cancers","volume":"32","author":"Ferris","year":"2014","journal-title":"JCO"},{"key":"10.1016\/j.suc.2019.09.003_bib57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2017.00149","article-title":"Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib58","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/1535-7163.MCT-09-0556","article-title":"Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses","volume":"8","author":"Kishimoto","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.suc.2019.09.003_bib59","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A\u00a0phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.suc.2019.09.003_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw378.06","article-title":"The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma","volume":"27","author":"Curti","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib61","doi-asserted-by":"crossref","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2017-CT026","article-title":"Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial","volume":"77","author":"Silk","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.suc.2019.09.003_bib62","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","article-title":"Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma","volume":"35","author":"Andtbacka","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.suc.2019.09.003_bib63","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Karapanagiotou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suc.2019.09.003_bib64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","article-title":"A\u00a0phase II study of REOLYSIN((R)) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","volume":"79","author":"Mahalingam","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suc.2019.09.003_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2019.09.003_bib66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0011-3840(99)80803-X","article-title":"Hyperthermic regional perfusion for melanoma and sarcoma of the limbs","volume":"36","author":"Fraker","year":"1999","journal-title":"Curr Probl Surg"},{"key":"10.1016\/j.suc.2019.09.003_bib67","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11864-004-0009-3","article-title":"Management of in-transit melanoma of the extremity with isolated limb perfusion","volume":"5","author":"Fraker","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","article-title":"Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety","volume":"15","author":"Moreno-Ramirez","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.suc.2019.09.003_bib69","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib70","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1245\/s10434-009-0563-9","article-title":"Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis","volume":"16","author":"Santillan","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib71","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/02656730701805520","article-title":"Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma","volume":"24","author":"M\u00f6ller","year":"2008","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.suc.2019.09.003_bib73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archsurg.1995.01430010045009","article-title":"Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions","volume":"130","author":"Vrouenraets","year":"1995","journal-title":"Arch Surg"},{"key":"10.1016\/j.suc.2019.09.003_bib74","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9","article-title":"Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion","volume":"14","author":"Thompson","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib75","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jso.23540","article-title":"Isolated limb infusion: technical aspects","volume":"109","author":"Kroon","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib76","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","article-title":"Outcomes following isolated limb infusion for melanoma. a 14-year experience","volume":"15","author":"Kroon","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib77","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1245\/s10434-017-6107-9","article-title":"Isolated limb infusion: a single-center experience with over 200 infusions","volume":"24","author":"O\u2019Donoghue","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib78","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1245\/s10434-016-5150-2","article-title":"Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma","volume":"23","author":"Dossett","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib79","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-019-07288-w","article-title":"Long\u2013term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: an international multicenter analysis","author":"Miura","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib80","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejso.2005.10.009","article-title":"Repeat isolated limb perfusion with TNF\u03b1 and melphalan for recurrent limb melanoma after failure of previous perfusion","volume":"32","author":"Noorda","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib81","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1245\/s10434-011-2151-z","article-title":"A\u00a0multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities","volume":"19","author":"Chai","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib82","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2019.09.003_bib83","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2019.09.003_bib84","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2019.09.003_bib85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib86","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2019.09.003_bib87","doi-asserted-by":"crossref","unstructured":"Agarwala S, Ross M, Zager J, et\u00a0al. Interim results of a Phase 1b\/2 study of PV-10 and anti-PD-1 in advanced melanoma. International Meeting of the Society of Melanoma Research [abstract]. Manchester, England, October 24\u201327, 2018.","DOI":"10.1200\/JCO.2019.37.15_suppl.9559"},{"key":"10.1016\/j.suc.2019.09.003_bib88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","article-title":"Robust antitumor responses result from local chemotherapy and CTLA-4 blockade","volume":"6","author":"Ariyan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.suc.2019.09.003_bib89","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib90","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.suc.2019.09.003_bib91","article-title":"Efficacy analysis of MASTERKEY-265 Phase 1b study of talimogene laherparepvec and pembrolizumab for unresectable stage IIIB-IV melanoma. [abstract]","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suc.2019.09.003_bib92","doi-asserted-by":"crossref","first-page":"TPS9598","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS9598","article-title":"A\u00a0phase 1\/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265)","volume":"34","author":"Long","year":"2016","journal-title":"JCO"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610919301215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610919301215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:11:51Z","timestamp":1758539511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610919301215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0039610919301215"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2019.09.003","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Locoregionally Advanced Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2019.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}